anti cd86 (Cell Signaling Technology Inc)
97
Structured Review
Cell Signaling Technology Inc
anti cd86
Anti Cd86, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 277 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+cd86+antibody/CD86+Rabbit+mAb/pm42867565-169-13-17
Average 97 stars, based on 277 article reviews
Anti Cd86, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 277 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rabbit+anti+cd86+antibody/CD86+Rabbit+mAb/pm42867565-169-13-17
Average 97 stars, based on 277 article reviews
anti cd86 - by Bioz Stars,
2026-10
97/100 stars
Images
Related Articles
Incubation:Article Title: The glutamine metabolic switch influences the response of neonatal intestinal macrophages to breast milk. Article Snippet: .. After cooling and washing with PBS, the 407 sections were incubated overnight at 4°C with a Article Title: The Glutamine Metabolic Switch Influences the Response of Neonatal Intestinal Macrophages to Breast Milk Article Snippet: .. After cooling and washing with PBS, the sections were incubated overnight at 4°C with a Article Title: Complement Inhibition Alleviates Cholestatic Liver Injury Through Mediating Macrophage Infiltration and Function in Mice Article Snippet: The sections were then incubated with iF555-Tyramide (G1233, Servicebio, 1:500 dilution) at room temperature for 10 min, followed by heating in a microwave repair for 8 min in EDTA (pH 8.0). .. The sections were incubated with Article Title: M2 macrophage-mediated tigecycline nanoparticles for combating CRKP pneumonia via antibacterial and immunomodulatory therapy. Article Snippet: Pneumonia caused by carbapenem-resistant Klebsiella pneumoniae (CRKP) has a high mortality rate and exhibits multiple drug resistance, making current antibacterial treatments of limited efficacy.. To address the challenges of ineffective drug accumulation at the infection site and excessive inflammation leading to tissue damage, this study developed a cell-based nanobionic drug delivery system (denoted as PT@M2, PLGA-TIG nanoparticles loaded into M2 macrophages).. This system encapsulates poly(lactic-co-glycolic acid) (PLGA) loaded with tigecycline within M2-type macrophages, thereby achieving stable circulation, rapid release in acidic microenvironments, and targeted delivery to the lungs. other:Article Title: Circadian disruption exacerbates MASH by reducing Akkermansia muciniphila via the FXR-CYP7A1-bile acid axis Article Snippet: Cell-Signaling:Article Title: M2 macrophage-mediated tigecycline nanoparticles for combating CRKP pneumonia via antibacterial and immunomodulatory therapy. Article Snippet: Pneumonia caused by carbapenem-resistant Klebsiella pneumoniae (CRKP) has a high mortality rate and exhibits multiple drug resistance, making current antibacterial treatments of limited efficacy.. To address the challenges of ineffective drug accumulation at the infection site and excessive inflammation leading to tissue damage, this study developed a cell-based nanobionic drug delivery system (denoted as PT@M2, PLGA-TIG nanoparticles loaded into M2 macrophages).. This system encapsulates poly(lactic-co-glycolic acid) (PLGA) loaded with tigecycline within M2-type macrophages, thereby achieving stable circulation, rapid release in acidic microenvironments, and targeted delivery to the lungs. Immunofluorescence:Article Title: Manganese-based immunotherapy synergized with novel supramolecular hydrogel: Advancing localized immune activation strategies in squamous cell carcinoma Article Snippet: Head and neck squamous cell carcinoma (HNSCC) presents significant challenges for its treatment, especially for the treatment aimed at preserving maxillofacial function due to its complex anatomical structure, resistance to radiotherapy and chemotherapy, and low intertumoral immunogenicity.. In this study, we introduce a novel approach employing manganese-based immunotherapy (Mn-IT) for the effective treatment of HNSCC.. Firstly, we used a tumor-immune cell co-culture system to demonstrate that Mn2+ enhances immune cytotoxicity in HNSCC via cGAS-STING activation. |